TR200201146T2 - Sertralin hidrokorid polimorfik formları. - Google Patents

Sertralin hidrokorid polimorfik formları.

Info

Publication number
TR200201146T2
TR200201146T2 TR2002/01146T TR200201146T TR200201146T2 TR 200201146 T2 TR200201146 T2 TR 200201146T2 TR 2002/01146 T TR2002/01146 T TR 2002/01146T TR 200201146 T TR200201146 T TR 200201146T TR 200201146 T2 TR200201146 T2 TR 200201146T2
Authority
TR
Turkey
Prior art keywords
sertraline
hydrocoride
sertraline hydrochloride
polymorphic forms
polymorphic
Prior art date
Application number
TR2002/01146T
Other languages
English (en)
Turkish (tr)
Inventor
Adriaan Van Der Schaaf Paul
Schwarzenbach Franz
Kirner Hans-Jorg
Szelagiewicz Martin
Marcolli Claudia
Burkhard Andreas
Peter Regine
Original Assignee
Ciba Specialty Chemicals Holding Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8243113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200201146(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Specialty Chemicals Holding Inc. filed Critical Ciba Specialty Chemicals Holding Inc.
Publication of TR200201146T2 publication Critical patent/TR200201146T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TR2002/01146T 1999-10-29 2000-10-23 Sertralin hidrokorid polimorfik formları. TR200201146T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99810981 1999-10-29

Publications (1)

Publication Number Publication Date
TR200201146T2 true TR200201146T2 (tr) 2004-12-21

Family

ID=8243113

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/01146T TR200201146T2 (tr) 1999-10-29 2000-10-23 Sertralin hidrokorid polimorfik formları.

Country Status (17)

Country Link
US (2) US6872853B1 (enExample)
EP (1) EP1224160B1 (enExample)
JP (1) JP2003513062A (enExample)
CN (1) CN1384816A (enExample)
AR (1) AR026293A1 (enExample)
AT (1) ATE409684T1 (enExample)
AU (1) AU1386301A (enExample)
CA (1) CA2387135A1 (enExample)
DE (1) DE60040406D1 (enExample)
HU (1) HUP0203559A3 (enExample)
IL (2) IL149050A0 (enExample)
MX (1) MXPA02004255A (enExample)
MY (1) MY141509A (enExample)
TR (1) TR200201146T2 (enExample)
TW (1) TWI260315B (enExample)
WO (1) WO2001032601A1 (enExample)
ZA (1) ZA200203254B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1630156A1 (en) * 1998-11-27 2006-03-01 Teva Pharmaceutical Industries Ltd Sertraline hydrochloride polymorphs
EP1133459B1 (en) * 1998-11-27 2006-01-11 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride form v
US6500987B1 (en) * 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
US7442838B2 (en) * 1999-10-29 2008-10-28 Ciba Specialty Chemicals Corp. Polymorphic forms of sertraline hydrochloride
US20050119351A1 (en) * 1999-10-29 2005-06-02 Van Der Schaaf Paul A. Polymorphic forms of sertraline hydrochloride
EP1774965A3 (en) * 1999-12-21 2007-10-10 Teva Pharmaceutical Industries Ltd Novel sertraline hydrochloride polymorph, processes for preparing them, compositions containing them and methods of using them
PL356452A1 (en) * 1999-12-21 2004-06-28 Teva Pharmaceutical Industries Ltd. Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
IN192343B (enExample) * 2000-05-26 2004-04-10 Ranbaxy Lab Ltd
WO2002096859A1 (en) * 2001-05-31 2002-12-05 Orion Corporation Fermion Process for preparing sertraline hydrochloride polymorphic form ii
CA2483569A1 (en) * 2002-04-29 2003-11-13 Tamar Nidam Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
EP1527617A4 (en) * 2002-06-27 2006-01-04 Interdigital Tech Corp PAIR EXCHANGE TO PAIR USER EQUIPMENT MEASUREMENT INFORMATION BETWEEN RADIO NETWORK CONTROLLERS
US7186863B2 (en) 2003-05-23 2007-03-06 Transform Pharmaceuticals, Inc. Sertraline compositions
EP1682483B1 (en) * 2003-11-04 2010-05-26 Cipla Ltd. Process for the preparation of polymorphs of sertraline hydrochloride
EP1711493A2 (en) * 2004-02-06 2006-10-18 CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement Crystalline forms of zolmitriptan
WO2007008317A2 (en) * 2005-06-09 2007-01-18 Teva Pharmaceutical Industries Ltd. Process for preparation of sertraline hydrochloride form i
US7518019B2 (en) 2006-06-01 2009-04-14 Hetero Drugs Limited Processes for preparing sertraline hydrochloride crystalline forms
CA2594198A1 (en) * 2007-07-20 2009-01-20 Apotex Pharmachem Inc. A novel process for the preparation of sertraline hydrochloride form ii
US9993793B2 (en) 2010-04-28 2018-06-12 The Procter & Gamble Company Delivery particles
US9186642B2 (en) 2010-04-28 2015-11-17 The Procter & Gamble Company Delivery particle
MX2013010981A (es) 2011-04-07 2013-10-30 Procter & Gamble Composiciones acondicionadoras con deposito mejorado de microcapsulas de poliacrilato.
CN103458858B (zh) 2011-04-07 2016-04-27 宝洁公司 具有增强的聚丙烯酸酯微胶囊的沉积的洗发剂组合物
CN103458859A (zh) 2011-04-07 2013-12-18 宝洁公司 具有增强的聚丙烯酸酯微胶囊的沉积的个人清洁组合物
CN105061217A (zh) * 2015-06-30 2015-11-18 徐静 枸橼酸舍曲林的2种晶型及其制备方法
MX2023004231A (es) 2020-10-16 2023-04-21 Procter & Gamble Composiciones de producto de consumo que comprenden una poblacion de encapsulados.
MX2023004232A (es) 2020-10-16 2023-04-21 Procter & Gamble Composiciones de productos de consumo con al menos dos poblaciones de encapsulados.
US12486478B2 (en) 2020-10-16 2025-12-02 The Procter & Gamble Company Consumer products comprising delivery particles with high core:wall ratios
CN112552188B (zh) * 2020-12-17 2023-07-28 山西仟源医药集团股份有限公司 盐酸舍曲林晶型i的制备方法
CN113588626B (zh) * 2021-08-24 2024-05-24 上海师范大学 一种苯丙氨酸对映体的拉曼光谱检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US5082970A (en) 1991-03-06 1992-01-21 Pfizer Inc. Process for recycling amine isomer
GB9114947D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5734083A (en) * 1996-05-17 1998-03-31 Torcan Chemical Ltd. Sertraline polymorph
HU222341B1 (hu) 1996-12-18 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Eljárás sertralin előállítására és az eljárásban alkalmazott intermedier
EP0928784B1 (en) 1997-12-11 2002-06-12 TORCAN CHEMICAL Ltd Sertraline polymorph having improved water solubility
HUP0101322A3 (en) 1998-03-18 2002-06-28 Ciba Sc Holding Ag Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
JP2000026378A (ja) 1998-07-03 2000-01-25 Sumika Fine Chemicals Co Ltd 塩酸セルトラリンの製法
US6500987B1 (en) 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
EP1133459B1 (en) * 1998-11-27 2006-01-11 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride form v
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
PL356452A1 (en) 1999-12-21 2004-06-28 Teva Pharmaceutical Industries Ltd. Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them

Also Published As

Publication number Publication date
US6939992B2 (en) 2005-09-06
HUP0203559A2 (hu) 2003-03-28
AU1386301A (en) 2001-05-14
US6872853B1 (en) 2005-03-29
HUP0203559A3 (en) 2008-01-28
MXPA02004255A (es) 2002-10-17
ATE409684T1 (de) 2008-10-15
EP1224160B1 (en) 2008-10-01
JP2003513062A (ja) 2003-04-08
US20040132828A1 (en) 2004-07-08
ZA200203254B (en) 2003-07-22
WO2001032601A1 (en) 2001-05-10
IL149050A0 (en) 2002-11-10
MY141509A (en) 2010-05-14
CA2387135A1 (en) 2001-05-10
DE60040406D1 (de) 2008-11-13
IL149050A (en) 2007-03-08
AR026293A1 (es) 2003-02-05
EP1224160A1 (en) 2002-07-24
TWI260315B (en) 2006-08-21
CN1384816A (zh) 2002-12-11

Similar Documents

Publication Publication Date Title
TR200201146T2 (tr) Sertralin hidrokorid polimorfik formları.
UY27304A1 (es) Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
PA8501801A1 (es) Inhibidores triciclicos de polimerasas (adp - polirribosas)
ES2112848T3 (es) Nuevos derivados de la n-acil-2,3-benzodiazepina.
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
ECSP056020A (es) Inhibidores del factor inhibidor de la migración de los macrofagos y metodos para su identificacion
PT915898E (pt) Forma i cristalina de claritromicina
ES2213732T3 (es) Nuevos esteres derivados de compuestos fenil-ciclohexil sustituidos.
HRP20010514B1 (en) Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament
BR0316375A (pt) Diazinopirimidinas
IL183244A0 (en) Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride
AR040278A1 (es) Ligandos del receptor de glucocorticoides para el tratamiento de trastornos metabolicos
EP1208092A4 (en) SULPHONAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS
DE69229339D1 (de) Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung
AR036137A1 (es) Sales novedosas de derivados anticonvulsivos
AR024494A1 (es) Proceso para la preparacion de derivados de ciclopentano sustituido y novedosas estructuras cristalinas de los mismos
NO20031743L (no) Krystallinsk venlafaxinbase og nye polyformer av venlafaxin- hydroklorid, samt fremgangsmåte for fremstilling derav
IT1319234B1 (it) Processo di preparazione di gabapentina.
IT1318535B1 (it) Processo per la preparazione di sali farmaceuticamente accettabili di(ss,rs)-s-adenosil-l-metionina.
ES2029879T3 (es) Procedimiento para producir derivados de aminas sustituidas.
ES2185967T3 (es) Procedimiento para preparar derivados acidos beta-amino-alfa-hidroxi.
BR0314838A (pt) Sistema de liberação controlada, e, processo para preparar comprimidos de liberação controlada de temozolomida
ATE552234T1 (de) Cyclohexanderivate und verfahren zu deren herstellung
BR0015877A (pt) Polimorfo v de torasemida
BR0010961A (pt) Composto, composição farmacêutica, e, métodos para tratar epilepsia, ataques de tontura, hipocinésia, e distúrbios cranianos, distúrbios neurodegenerativos, depressão, ansiedade, pânico, dor, distúrbios neuropatológicos e distúrbios do sono